Nonalcoholic Steatohepatitis

DUR-928 compound continues phase 1 clinical trials

A therapeutic compound developed at Virginia Commonwealth University, which may have broad applicability in acute organ injuries and in several metabolic diseases such as nonalcoholic fatty liver disease and nonalcoholic ...

May 19, 2015
popularity20 comments 0

Researchers link liver disease and drug metabolism

Researchers at the University of Arizona College of Pharmacy have discovered that nonalcoholic steatohepatitis (NASH), an increasingly common but often undiagnosed liver disease, could have significant medical implications ...

Jul 09, 2015
popularity12 comments 0

Non-alcoholic fatty liver disease (NAFLD) is one cause of a fatty liver, occurring when fat is deposited (steatosis) in the liver not due to excessive alcohol use. It is related to insulin resistance and the metabolic syndrome and may respond to treatments originally developed for other insulin-resistant states (e.g. diabetes mellitus type 2) such as weight loss, metformin and thiazolidinediones. Non-alcoholic steatohepatitis (NASH) is the most extreme form of NAFLD this being regarded as a major cause of cirrhosis of the liver of unknown cause.

This text uses material from Wikipedia licensed under CC BY-SA

Latest Spotlight News

Next steps in understanding brain function

The most complex piece of matter in the known universe is the brain. Neuroscientists have recently taken on the challenge to understand brain function from its intricate anatomy and structure. There is no sure way to go about ...

Is tailgating toxic?

While tailgating this football season you may want to take a step back from the grill and generator—for your health.